A 62-year-old man is evaluated in the surgical intensive care unit. He was admitted 6 days… — USMLE Step 3

A 62-year-old man is evaluated in the surgical intensive care unit. He was admitted $6$ days ago following an emergency exploratory laparotomy and small bowel resection for mesenteric ischemia. Postoperatively, he developed a deep vein thrombosis in his right lower extremity and was started on a continuous intravenous unfractionated heparin infusion.

The patient's target activated partial thromboplastin time (aPTT) is $60-80$ seconds. His daily laboratory trends are shown below:

Hospital Day	Platelet count ( $/\text{mm}^3$ )	aPTT (seconds)
Day 1 (Baseline)	$320,000$	$28$
Day 2	$290,000$	$50$
Day 4	$210,000$	$65$
Day 6 (Today)	$145,000$	$52$

Today, the patient reports mild worsening of his right leg pain. Vital signs are temperature $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ ), blood pressure $135/82$ mmHg, heart rate $92$ /min, and respirations $16$ /min. Physical examination shows persistent right calf swelling and a new area of erythema and induration at a recent peripheral intravenous catheter site.

Based on the clinical and laboratory monitoring parameters provided, which of the following is the most appropriate next step in management?

A
Increase the unfractionated heparin infusion rate
B
Switch from unfractionated heparin to subcutaneous enoxaparin
Discontinue unfractionated heparin and initiate an argatroban infusionCevap
D
Continue the current heparin infusion and order a serotonin release assay
E
Discontinue unfractionated heparin and administer a platelet transfusion

Cevap

Discontinue unfractionated heparin and initiate an argatroban infusion

This patient has developed Heparin-Induced Thrombocytopenia (HIT) Type II. The diagnosis is strongly suggested by the '4Ts': Thrombocytopenia (a drop of >50% from the baseline of

320,000/\text{mm}^3

145,000/\text{mm}^3

), Timing (onset between days 5-10 of heparin therapy), Thrombosis (suspected new thrombosis at the IV site causing erythema and induration, and worsening leg pain), and no oTher obvious causes. When a patient has a high clinical probability of HIT, all heparin-containing products (including unfractionated heparin flushes) must be discontinued immediately. Due to the paradoxically high risk of life-threatening thrombosis (e.g., stroke, myocardial infarction, limb ischemia), the patient requires immediate therapeutic anticoagulation with a non-heparin alternative, most commonly a direct thrombin inhibitor such as argatroban or bivalirudin, or fondaparinux.

Adım Adım Çözüm

Analyze the laboratory trends specifically looking at the platelet count relative to baseline, not just the absolute values.

The platelet count dropped from

320,000/\text{mm}^3

145,000/\text{mm}^3

Recognizing a relative drop of

>50\%

is essential, even if the absolute nadir (

145,000

) is only marginally below the normal reference range.

Evaluate the clinical timeline and findings to calculate a 4T score for Heparin-Induced Thrombocytopenia (HIT).

The patient scores high on the 4T scale:

>50\%

platelet drop (

2

points), onset on Day

6

(

2

points), new possible thrombosis at the IV site/worsening leg pain (

2

points), and no other obvious cause for thrombocytopenia (

2

points).

A high 4T score indicates a high pretest probability of HIT, necessitating immediate clinical action.

Determine the appropriate empiric treatment modifications for highly suspected HIT.

All heparin products must be immediately discontinued, and an alternative non-heparin anticoagulant (such as the direct thrombin inhibitor argatroban) must be initiated.

Continuing heparin or switching to LMWH will fuel the prothrombotic state. Delaying treatment for confirmatory testing (like an SRA) is contraindicated.

Anahtar Kavram

Monitoring for and managing Heparin-Induced Thrombocytopenia (HIT)

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru